1. Introduction
===============

The rhizome of *Smilacis glabrae* Roxb (family Smilacaceae) is a well-known traditional Chinese medicine (TCM) with great medicinal values. It is officially listed in the Chinese Pharmacopoeia and has been widely used for detoxification treatments, relieving dampness and as a diuretic \[[@B1-molecules-19-10427]\]. It was also consumed as a functional food. People in China like to use it to boil soup or tea for clearing damp. Besides, it is one of the main ingredients of turtle jelly (Gui-ling-gao), a traditional functional food popular in Southern China and Hong Kong. Phytochemical studies have shown the presence of abundant compounds in *S. glabrae*, such as flavonoids, phenolic acids and phenylpropanoid glycosides \[[@B2-molecules-19-10427],[@B3-molecules-19-10427]\], among which flavonoids were considered to be the primary bioactive constituents of the herbal medicine. Astilbin, neoastilbin, isoastilbin, neoisoastilbin, engeletin and isoengeletin were considered as marker constituents included in *S. glabrae*. These six flavonoids were reported to possess various biological activities, involving anti-inflammatory, antioxidative, antibacterial and antitumor properties \[[@B4-molecules-19-10427],[@B5-molecules-19-10427],[@B6-molecules-19-10427],[@B7-molecules-19-10427],[@B8-molecules-19-10427],[@B9-molecules-19-10427],[@B10-molecules-19-10427]\]. Some analytical methods have been used for qualitative or quantitative analysis of some of these bioactive constituents in *S. glabrae*. Li *et al.* identified the main constituents in *Rhizoma Smilacis glabrae* by means of UHPLC-DAD-MS \[[@B3-molecules-19-10427]\]. Chen *et al.* established an HPLC method for determination of five compounds in *Rhizoma Smilacis glabrae* \[[@B11-molecules-19-10427]\]. Although these methods have made significant contributions to the studies of the quality control of *Smilacis glabrae*, they have limitations, such as taking a long time to perform or being either qualitative or quantitative. Less effort has been dedicated to further characterize minor new components or the rapid determination of active components, so a new method is required to address the limitations of the previous techniques.

The present work aimed at developing a rapid and simple UHPLC-ESI-MS method for analyzing and discovering minor new constituents, and quantifying the active components in *Smilacis glabrae*. The advantages of this method comprised high-speed detection, excellent peak shapes, and less solvent usage. With the new method it took less than 10 min to detect 56 compounds of *Smilacis glabrae*, including six new compounds. Further, six marker flavonoids were quantitatively determined in negative ionization mode and five batches of *Smilacis glabrae* were analyzed for assessment of quality consistence. This is the first time for determination of multiple components in *Smilacis glabrae* using UHPLC-ESI/LTQ-Orbitrap-MS.

2. Results and Discussion
=========================

2.1. Optimization of Chromatographic Conditions
-----------------------------------------------

To improve the resolution and sensitivity of the analysis but reduce the analytical time, the mobile phase system was optimized. To inhibit ionization of the acidic ingredients in *Smilacis glabrae* extract, formic acid was added to the mobile phase. Two mobile phase systems, methanol-aqueous solution and acetonitrile-aqueous solution were compared. Both negative and positive modes were examined. Generally, in positive mode, low abundance of \[M+H\]^+^, \[M+NH~4~\]^+^ ions and few product ions were observed, while, in negative ion mode, a series of \[M-H\]^−^ ions and/or adduct ions (\[M+HCOOH-H\]^−^) appeared with sufficient abundance. Thus the negative ion mode was chosen and the \[M-H\]^−^/(\[M+HCOOH-H\]^−^) ions were further subjected to LC-MS^n^ analysis.

2.2. Identification of Chemical Constituents in Smilacis glabrae Extract
------------------------------------------------------------------------

The reference standards and *Smilacis glabrae* sample were analyzed by using the optimized UHPLC-ESI-MS^n^ method. The TIC chromatograms of the six reference standards and the extract of *Smilacis glabrae* in negative ESI mode were shown in [Figure 1](#molecules-19-10427-f001){ref-type="fig"}. Fifty six peaks were observed. The MS data showed high precision with all the mass accuracies within 5 ppm. For most of the constituents, a \[M-H\]^−^ peak was observed. Due to the use of formic acid in mobile phase, there were additional ions of \[M+46-H\]^−^ corresponding to \[M+HCOOH-H\]^−^ in negative ion mode. These results provided valuable information for confirming accurate molecular weights and composition of the constituents. The 56 compounds including six new ones were tentatively identified on the basis of their retention behaviors, accurate molecular weight and MS^n^ fragment data, or by comparison with reference standards or literature data (chemical structures of the compounds corresponding to the peaks shown in [Figure 1](#molecules-19-10427-f001){ref-type="fig"} below can be found in [Figure 1 in the Supplementary](#app1-molecules-19-10427){ref-type="app"}). The corresponding quasimolecular ions and their fragment ions in the MS^n^ spectra are listed in [Table 1](#molecules-19-10427-t001){ref-type="table"}.

![UHPLC-(-) ESI-MS total ion chromatograms of a mixture of six standards (**A**) and the extract of *Smilacis glabrae* (**B**).](molecules-19-10427-g001){#molecules-19-10427-f001}

The identified compounds can be classified into three classes, namely flavonoids, phenolic acids and phenylpropanoid glycosides. Four flavanonol isomers (compounds **30**, **31**, **34** and **35**) were unambiguously identified by the same deprotonated ions at *m/z* 449 (C~21~H~21~O~11~) and the same product ions at *m/z* 303 and *m/z* 285, and they could be distinguished through their UV absorption and elution order when compared to reference standards. Neoastilbin (**30**) with 2*S*,3*S* configuration and astilbin (**31**) with 2*R*,3*R* configuration had the same UV~max~ absorption at 290 nm, while neoisoastilbin (**34**) with 2*S*,3*R* configuration and isoastilbin (**35**) with 2*R*,3*S* configuration had the same UV absorption at 295--296 nm (see [Figure 2 in the Supplementary](#app1-molecules-19-10427){ref-type="app"}), the latter caused a red shift of 5--6 nm, and the elution order of the four flavanonol isomers were 2*S*,3*S* \> 2*R*,3*R* \> 2*S*,3*R* \> 2*R*,3*S*. The four flavanonols were the main constituents of *S. glabrae*. To our surprise, compounds **19**, **21**, **25** and **29** had the same deprotonated ions at *m/z* 629 (C~30~H~29~O~15~) and the same fragment ions ([Figure 2](#molecules-19-10427-f002){ref-type="fig"}), which demonstrated they were also diastereomers. In the MS^2^ spectra, the product ions at *m/z* 449 \[M-H-C~9~H~8~O~4~\] and *m/z* 303 \[M-H-C~9~H~8~O~4~-rhamnose\] suggested the four diastereomers were the derivatives of the four configurationally different astilbins. In addition, two prominent MS^2^ product ions were observed at *m/z* 475 and *m/z* 483, respectively, for the neutral loss of CO~2~ + C~6~H~6~O~2~ and for the loss of a rhamnose, which indicated they had the same substituent group and substituent site. The four isomers could also be distinguished through their UV absorption. Compounds **19** and **21** had the same UV absorption at 289 nm, while compounds **25** and **29** had the same UV absorption at 295 nm (see [Figure 2 in the Supplementary](#app1-molecules-19-10427){ref-type="app"}), which indicated that compounds **19** and **21** had the 2*S*,3*S* or 2*R*,3*R* configuration, while compounds **25** and **29** had the 2*S*,3*R* or 2*R*,3*S* configuration. As the elution order was 2*S*,3*S* \> 2*R*,3*R* \> 2*S*,3*R* \> 2*R*,3*S*, thus compounds **19**, **21**, **25** and **29** were tentatively identified as 8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted neoastilbin, 8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted astilbin, 8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted neoisoastilbin and 8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted isoastilbin, respectively. Similarly, compounds **38** and **42** were unambiguously identified as engeletin (**38**) and isoengeletin (**42**) based on reference standards, and compounds **24** and **28** were tentatively identified as 8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted engeletin and 8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted isoengeletin, respectively ([Figure 3 in the Supplementary](#app1-molecules-19-10427){ref-type="app"}). Compounds **19**, **21**, **24**, **25**, **28** and **29** were identified as new compounds, but their absolute configurations could not be determined.

2.3. Method Validation of the Quantitative Analysis
---------------------------------------------------

The calibration curves, linear ranges, limit of quantification (LOQ) and repeatability of six analytes were performed using the above-developed UHPLC-ESI-MS method ([Table 2](#molecules-19-10427-t002){ref-type="table"}). Reasonable correlation coefficient values (*r*^2^ ≥ 0.9981) indicated good correlations between investigated standards concentrations and their peak areas within the ranges tested. The ranges of LOQ for all the analytes were from 0.011 to 0.067 μg/mL, respectively. The repeatability present as RSD (*n* = 6) was between 1.77% and 2.37% of the 6 analytes. The overall intra- and inter-day precisions (RSD) of the six analytes were in the range from 1.03% to 3.19%, and 0.76% to 3.91% ([Table 2](#molecules-19-10427-t002){ref-type="table"}), respectively. The developed method had good accuracy with the RSD of the recoveries were between 1.49% and 4.73% ([Table 2](#molecules-19-10427-t002){ref-type="table"}). Therefore, the results demonstrated that the UHPLC-ESI-MS method was sensitive, precise, and accurate enough for quantitative evaluation of *Smilacis glabrae*.

molecules-19-10427-t001_Table 1

###### 

Identification of the chemical constituents of *Smilacis glabrae* by UHPLC-ESI-MS^n^ analysis.

  Peak No.   *t*~R~ (min)   Selected Ion    Observed Mass (*m/z*)   Calculated Mass (*m/z*)   Formula           MS/MS Fragmentation Patterns      Identifieation
  ---------- -------------- --------------- ----------------------- ------------------------- ----------------- --------------------------------- -----------------------------------------------------------------------------------------------------------
  1 ^a^      1.15           \[M-H\]^−^      173.0457                173.0450                  C~7~H~9~O~5~      173→155, 129, 111                 shikimic acid
  2          1.62           \[M-H\]^−^      117.0195                117.0188                  C~4~H~5~O~4~      117→99, 73                        succinic acid
  3          2.32           \[M-H\]^−^      359.0984                359.0978                  C~15~H~19~O~10~   359→197, 182                      syringic acid-4-*O*-β-[d]{.smallcaps}-glucopyranoside
  4          2.34           \[M+COOH\]^−^   255.0512                255.0505                  C~11~H~11~O~7~    255→209, 193, 179, 165            3,4-dihydroxy-5-methoxycinnamic acid
  5          2.47           \[M+COOH\]^−^   345.1191                345.1186                  C~15~H~21~O~9~    345→299                           rhodioloside
  6 ^a^      2.70           \[M-H\]^−^      153.0194                153.0188                  C~7~H~5~O~4~      153→109                           protocatechuic acid
  7          2.91           \[M+COOH\]^−^   197.0458                197.0450                  C~9~H~9~O~5~      197→153                           syringic acid
  8          2.97           \[M-H\]^−^      387.1296                387.1291                  C~17~H~23~O~10~   387→207, 177                      3-(β-[d]{.smallcaps}-glucopyranosyloxy)-1-(4-hydroxy-3,5-dimethoxyphenyl)-1-propanone
  9          3.08           \[M-H\]^−^      577.1346                577.1346                  C~30~H~25~O~12~   577→559, 451, 425, 407, 289       procyanidin B
  10 ^a^     3.13           \[M-H\]^−^      289.0720                289.0712                  C~15~H~13~O~6~    289→271, 245, 205,179,151         catechin
  11         3.19           \[M-H\]^−^      239.0564                239.0556                  C~11~H~11~O~6~    239→221, 195, 179, 177, 149       syringic acid acetate
  12         3.36           \[M-H\]^−^      315.1074                315.1080                  C~14~H~19~O~8~    315→153                           3,4-dihydroxyphenethyl glucoside
  13 ^a^     3.45           \[M-H\]^−^      469.1141                469.1135                  C~24~H~21~O~10~   469→315, 289                      (2 *R*,3*S*)-8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted catechin
  14 ^a^     3.55           \[M-H\]^−^      335.0777                335.0767                  C~16~H~15~O~8~    335→291, 179, 135                 3-*O*-caffeoylshikimic acid
  15 ^a^     3.58           \[M-H\]^−^      561.1397                561.1397                  C~30~H~25~O~11~   561→543, 435, 289                 3\',4\',5,7-tetrahydroxyflavan(4°8)-3,3\',4\',5,7-pentahydroxyflavan
  16 ^a^     3.61           \[M-H\]^−^      289.0722                289.0712                  C~15~H~13~O~6~    289→271, 245, 205, 179, 151       epicatechin
  17 ^a^     3.74           \[M-H\]^−^      335.0777                335.0767                  C~16~H~15~O~8~    335→291, 179, 135                 4-*O*-caffeoylshikimic acid
  18 ^a^     3.76           \[M-H\]^−^      179.0350                179.0344                  C~9~H~7~O~4~      179→161, 135                      caffeic acid
  19 ^b^     3.93           \[M-H\]^−^      629.1514                629.1506                  C~30~H~29~O~15~   629→483, 475, 449, 303, 285       8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted neoastilbin
  20         4.04           \[M-H\]^−^      465.1041                465.1033                  C~21~H~21~O~12~   465→421, 297                      4-*O*-β-[d]{.smallcaps}-(6-*O*-gentisoylglucopyranosyl)-vanillic acid
  21 ^b^     4.20           \[M-H\]^−^      629.1514                629.1506                  C~30~H~29~O~15~   629→483, 475, 449, 303, 285       8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted astilbin
  22         4.23           \[M-H\]^−^      339.0721                339.0716                  C~15~H~15~O~9~    339→193                           smiglanin
  23 ^a^     4.39           \[M-H\]^−^      335.0777                335.0767                  C~16~H~15~O~8~    335→291, 179, 135                 5-*O*-caffeoylshikimic acid
  24 ^b^     4.44           \[M-H\]^−^      613.1565                613.1557                  C~30~H~29~O~14~   613→467, 459, 433, 287            8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted engeletin
  25 ^b^     4.56           \[M-H\]^−^      629.1514                629.1506                  C~30~H~29~O~15~   629→483, 475, 449, 303, 285       8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted neoisoastilbin
  26         4.84           \[M-H\]^−^      301.0354                301.0348                  C~15~H~9~O~7~     301→283, 255, 215, 175, 151       quercetin
  27         4.97           \[M+COOH\]^−^   435.1297                435.1291                  C~21~H~23~O~10~   435→389, 227,195                  polydatin
  28 ^b^     5.06           \[M-H\]^−^      613.1565                613.1557                  C~30~H~29~O~14~   613→467, 459, 433, 287            8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted isoengeletin
  29 ^b^     5.12           \[M-H\]^−^      629.1514                629.1506                  C~30~H~29~O~15~   629→483, 475, 449, 303            8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted isoastilbin
  30 ^c^     5.29           \[M-H\]^−^      449.1099                449.1084                  C~21~H~21~O~11~   449→303, 285                      neoastilbin
  31 ^c^     5.63           \[M-H\]^−^      449.1099                449.1084                  C~21~H~21~O~11~   449→303, 285                      astilbin
  32 ^a^     5.72           \[M-H\]^−^      193.0511                193.0501                  C~10~H~9~O~4~     193→178, 161, 134                 ferulic acid
  33 ^a^     6.10           \[M-H\]^−^      303.0513                303.0505                  C~15~H~11~O~7~    303→285, 177, 125                 taxifolin
  34 ^c^     6.55           \[M-H\]^−^      449.1099                449.1084                  C~21~H~21~O~11~   449→303, 285                      neoisoastilbin
  35 ^c^     6.81           \[M-H\]^−^      449.1099                449.1084                  C~21~H~21~O~11~   449→303, 285                      isoastilbin
  36         6.86           \[M-H\]^−^      243.0665                243.0657                  C~14~H~11~O~4~    243→225, 201, 199, 175            piceatannol
  37         7.27           \[M-H\]^−^      433.1149                433.1135                  C~21~H~21~O~10~   433→287, 269                      neoengeletin
  38 ^c^     7.43           \[M-H\]^−^      433.1149                433.1135                  C~21~H~21~O~10~   433→287, 269                      engeletin
  39 ^a^     7.49           \[M-H\]^−^      359.0771                359.0767                  C~18~H~15~O~8~    359→341, 291, 239, 197            rosmarinic acid
  40         7.53           \[M-H\]^−^      433.1149                433.1135                  C~21~H~21~O~10~   433→287,269                       neoisoengeletin
  41         8.16           \[M-H\]^−^      693.2029                693.2031                  C~32~H~37~O~17~   693→517, 337                      helonioside A
  42 ^c^     8.20           \[M-H\]^−^      433.1149                433.1135                  C~21~H~21~O~10~   433→287,269                       isoengeletin
  43 ^a^     8.23           \[M-H\]^−^      451.1038                451.1029                  C~24~H~19~O~9~    451→341                           cinchonain Ia
  44         8.25           \[M-H\]^−^      693.2029                693.2031                  C~32~H~37~O~17~   693→357                           securoside A
  37         7.27           \[M-H\]^−^      433.1149                433.1135                  C~21~H~21~O~10~   433→287, 269                      neoengeletin
  45 ^a^     8.30           \[M-H\]^−^      451.1035                451.1029                  C~24~H~19~O~9~    451→341                           cinchonain Ib
  46         8.32           \[M-H\]^−^      227.0717                227.0708                  C~14~H~11~O~3~    227→209,185, 183, 159, 157, 143   resveratrol
  47 ^a^     8.35           \[M-H\]^−^      809.2293                809.2293                  C~40~H~41~O~18~   809→767, 663, 633                 smilaside G
  48 ^a^     8.36           \[M-H\]^−^      839.2408                839.2398                  C~41~H~43~O~19~   839→797, 693, 663, 517            smilaside J
  49 ^a^     8.38           \[M-H\]^−^      869.2502                869.2504                  C~42~H~45~O~20~   869→827, 693, 675                 smilaside L
  50         8.40           \[M-H\]^−^      777.2248                777.2242                  C~36~H~41~O~19~   777→735, 717, 601, 559            (3,6-di-O-feruloyl)-β-[d]{.smallcaps}-fructofuranosyl-(3,6-di-O-acetyl)-α-[d]{.smallcaps}-glucopyranoside
  51         8.42           \[M-H\]^−^      819.2354                819.2348                  C~38~H~43~O~20~   819→777, 643, 601, 513            smilaside C
  52         8.44           \[M-H\]^−^      923.2604                923.2610                  C~45~H~47~O~21~   923→881, 863, 747, 601, 483       smilaside E
  53         8.45           \[M-H\]^−^      953.2712                953.2715                  C~46~H~49~O~22~   953→911, 777, 735, 717, 289       smilaside B
  54 ^a^     8.48           \[M-H\]^−^      271.0614                271.0606                  C~15~H~11~O~5~    271→177, 151                      naringenin
  55         8.52           \[M-H\]^−^      965.2719                965.2715                  C~47~H~49~O~22~   965→923, 905, 789, 747, 483       smilaside D
  56         8.55           \[M-H\]^−^      995.2829                995.2821                  C~48~H~51~O~23~   995→953, 819, 777, 513            smilaside A

^a^ Compared with reference \[[@B3-molecules-19-10427]\]; ^b^ Identified as new compound; ^c^ Compared with reference standards.

![Proposed fragmentation pathways for compounds **19**, **21**, **25** and **29**.](molecules-19-10427-g002){#molecules-19-10427-f002}

2.4. Quantitative Analysis
--------------------------

The newly established analytical method was subsequently applied to determine the six compounds of *Smilacis glabrae*. The target compounds were identified based on comparison of retention time and mass information obtained from UHPLC-ESI-MS analysis of the reference standards. [Table 3](#molecules-19-10427-t003){ref-type="table"} showed the content determined for each compound. The results indicated that the amount of most components determined was similar in the five different batches.

molecules-19-10427-t002_Table 2

###### 

Summary of calibration curves, linear range, LOQ, repeatability, intra-day and inter-day precisions and recoveries for six analytes analyzed with the LC-MS system

  Analyte          Linear Range (μg/mL)   Calibration Curve (*n* = 7)   r^2^     LOQ (μg/mL)   Repeatability RSD (%)   Intra-day (RSD, %) (*n* = 6)   Inter-day (RSD, %) (*n* = 3)   Recoveries (*n* = 3)                                                  
  ---------------- ---------------------- ----------------------------- -------- ------------- ----------------------- ------------------------------ ------------------------------ ---------------------- ------------- --------------- ---------------- ---------
                                                                                                                                                                                     Initial (μg)           Spiked (μg)   Detected (μg)   Recoveries (%)   RSD (%)
  Neoastilbin      0.82−32.8              *y* = 8593.3 *x* + 281942     0.9993   0.016         2.37                    3.19                           3.05                           3.470                  2.628         5.872           96.27            3.51
                                                                                                                                                                                                            3.284         6.890           101.99           3.16
                                                                                                                                                                                                            3.940         7.085           95.63            1.65
  Astilbin         3.10−124.1             *y* = 8921.6 *x* + 16423      0.9991   0.062         1.86                    1.03                           0.76                           13.677                 9.932         22.963          97.27            2.57
                                                                                                                                                                                                            12.416        25.468          97.60            3.86
                                                                                                                                                                                                            14.900        27.916          97.69            2.66
  Neoisoastilbin   0.33−13.3              *y* = 8299.7 *x* + 165713     0.9988   0.067         1.91                    2.43                           2.49                           1.517                  1.064         2.342           90.77            4.73
                                                                                                                                                                                                            1.340         2.426           91.94            3.39
                                                                                                                                                                                                            1.606         3.205           102.65           3.83
  Isoastilbin      1.78--71.2             *y* = 8479.3 *x* + 161354     0.9981   0.018         2.15                    1.07                           0.79                           7.188                  5.702         12.485          96.86            1.80
                                                                                                                                                                                                            7.128         14.153          98.86            2.83
                                                                                                                                                                                                            8.555         15.011          95.35            2.30
  Engeletin        0.86--34.4             *y* = 4620.5 *x* − 107846     0.9992   0.017         1.77                    2.00                           3.91                           4.110                  2.756         7.038           102.51           2.14
                                                                                                                                                                                                            3.444         7.300           96.59            1.49
                                                                                                                                                                                                            4.132         8.271           100.39           2.37
  Isoengeletin     0.28--11.1             *y* = 4472.8 *x* − 12397      0.9991   0.011         1.94                    2.83                           2.86                           1.237                  0.896         2.152           100.95           2.34
                                                                                                                                                                                                            1.120         2.368           100.37           3.09
                                                                                                                                                                                                            1.134         2.506           97.18            4.50

molecules-19-10427-t003_Table 3

###### 

Contents of the six compounds in different batches of *Smilacis glabrae*.

  Analyte          Content (μg/g)                                
  ---------------- ---------------- -------- -------- ---------- --------
  Neoastilbin      2173.1           2735.9   2356.9   2537.4     2253.7
  Astilbin         8548.2           8996.1   9262.1   10,962.2   9988.6
  Neoisoastilbin   948.3            1046.4   971.2    1188.7     1097.3
  Isoastilbin      4493.2           4189.5   4257.9   2800.9     3461.3
  Engeletin        2587.2           2494.3   2682.1   1821.6     2047.6
  Isoengeletin     771.6            727.6    834.9    594.3      488.5

3. Experimental Section
=======================

3.1. Chemicals and Materials
----------------------------

HPLC grade acetonitrile and methanol were purchased from Fisher Chemicals (Fairlawn, NJ, USA). Formic acid of HPLC grade was purchased from Sigma Aldrich (St. Louis, MO, USA). Water (18.2 MΩ) was from a Milli-Q water system (Millipore, Bedford, MA, USA). Neoastilbin (**30**), astilbin (**31**), neoisoastilbin **(34**), isoastilbin (**35**), engeletin (**38**) and isoengeletin (**42**) were provided by Dr. Lixiong from the Guangdong Provincial Hospital of Chinese Medicine. Three batches of *Smilacis glabrae* originating from Guangdong Province, China were supplied by Kangmei Pharmaceutical Co. Ltd. (Puning, China). Two batches of *Smilacis glabrae* from the Hunan and Guangxi provinces of China were purchased from Er-tian-tang Pharmacy (Guangzhou, China). Voucher samples were deposited in the Laboratory of Chinese Materia Medica Preparation, Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine.

3.2. Standard Solutions and Sample Preparation
----------------------------------------------

The standard solution mixture of the six flavonoids was prepared by dissolving the reference substances in methanol to final concentration of 32.8 μg/mL for neoastilbin, 124.1 μg/mL for astilbin, 13.3 μg/mL for neoisoastilbin, 71.2 μg/mL for isoastilbin, 34.4 μg/mL for engeletin and 11.1 μg/mL for isoengeletin, respectively. Then, the standard solution mixture was diluted to 80%, 60%, 40%, 20%, 10%, 5% and 2.5% of the concentration of the original solution. All the standard solutions were stored at 4 °C.

The dried rhizome (0.2 g, 60 mesh) was accurately weighed and ultrasonically extracted by infusion with 25 mL water for 30 min. The extracted solution was centrifuged at 10,000 rpm for 10 min, and then filtered through a 0.22 m nylon membrane filter prior to injection for UHPLC-MS analysis.

3.3. Analytical System
----------------------

Chromatographic separation was performed on an Accela™ ultra high pressure liquid chromatography (UHPLC) system (Thermo Fisher Scientific, San Jose, CA, USA) comprising a UHPLC pump, a PDA detector, scanning from 200 to 400 nm, and an autosampler settled to 30 °C. The LC conditions were as follows: column: Agilent Eclipse Plus C18 (100 mm × 3.0 mm, 1.7 μm); mobile phase: acetonitrile (A) and water (B) both containing 0.1% (v/v) formic acid; gradient: 0 min, 10: 90; 1 min, 20: 80; 3--6.5 min, 23: 77; 7 min, 80: 20; 9--10 min, 100: 0 (A: B, v/v); flow rate: 0.3 mL/min; injection volume: 10 μL.

3.4. Qualitative Characteristic of Chemical Constituents
--------------------------------------------------------

Identification of chemical constituents in *Smilacis glabrae* extract was performed by UHPLC-ESI-MS^n^ analysis. MS analysis was performed using an LTQ Orbitrap^XL^ hybrid mass spectrometer (Thermo Fisher Scientific), fitted with an ESI source, and operated in negative ion mode, with a mass range of 100--1500 with resolution set at 30000 using the normal scan rate.

The data-dependent MS/MS events were always performed on the most intense ions detected in full scan MS. The MS/MS isolation width was 1 amu, and the normalized collision energy was 35% for all compounds. Nitrogen was used as sheath gas and helium served as the collision gas. The key optimized ESI parameters were as follows: source voltage: 3.8 kV; sheath gas (nitrogen): 50 L/min; auxiliary gas flow: 10 L/min; capillary voltage: --35.0 V; capillary temperature: 300.0 °C; tube lens: --110.0 V. The ion injection time used was 50.0 ms. MS scan functions and HPLC solvent gradients were controlled by the Xcalibur data system (Thermo Fisher Scientific). Data was collected and analyzed with Xcalibur 2.0.7 software (Thermo Fisher Scientific). The Orbitrap mass analyzer was calibrated according to the manufacturer's directions using a mixture of caffeine, methionine-arginine-phenylalanine-alanine-acetate (MRFA), sodium dodecyl sulfate, sodium taurocholate and Ultramark 1621 in an acetonitrile-methanol-water solution containing 1% acetic acid by direct injection at a flow rate of 5 μL/min in negative mode before analysis.

3.5. Validation of the Quantitative Analysis
--------------------------------------------

A calibration curve was used to determine the calculated concentration of the samples. The calibration curve of each compound was performed with at least six appropriate concentrations. The limit of quantification (LOQ) under the present chromatographic conditions was determined at signal-to-noise ratios (S/N) of 10.

Intra- and inter-day variations were chosen to determine the precision of the developed method. The precision was examined by five repetitive injections in the same day and in three consecutive days, respectively. The relative standard deviation (R.S.D.) was considered as the measure of precision.

The accuracy was evaluated by calculating the mean recoveries of six reference standards from the spiked standard solutions. A known amount of *Smilacis glabrae* sample was spiked with the standard solution at three different concentration levels. The high spiked amount was 1.2 times of the known amount sample, the middle spiked amount was 1.0 times of the known amount sample and the low spiked amount was 0.8 times of the known amount sample. The recovery percentages were calculated using to the following equation: (total detected amount -- original amount)/added amount ×100%.

4. Conclusions
==============

In this study, a total of 56 compounds, including six minor new ones, were simultaneously detected and identified by UHPLC-LTQ-Orbitrap-MS. Based on the qualitative analysis, a rapid method was established for quantitative analysis of six marker components in *Smilacis glabrae* extract. This is the first report on the comprehensive determination of chemical constituents in *S. glabrae* by UHPLC-LTQ-Orbitrap-MS. The results would provide the chemical support for the further pharmacokinetic studies and for the improvement of quality control of *Smilacis glabrae* and its preparations. The study also suggested that UHPLC-ESI/LTQ-Orbitrap mass spectrometry would be a powerful and reliable analytical tool for the characterization of chemical profile in complex chemical system, such as TCM preparations.
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